ZA200210268B - Use of secretin-receptor ligands in treatment of cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). - Google Patents

Use of secretin-receptor ligands in treatment of cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD).

Info

Publication number
ZA200210268B
ZA200210268B ZA200210268A ZA200210268A ZA200210268B ZA 200210268 B ZA200210268 B ZA 200210268B ZA 200210268 A ZA200210268 A ZA 200210268A ZA 200210268 A ZA200210268 A ZA 200210268A ZA 200210268 B ZA200210268 B ZA 200210268B
Authority
ZA
South Africa
Prior art keywords
treatment
pulmonary disease
chronic obstructive
obstructive pulmonary
cystic fibrosis
Prior art date
Application number
ZA200210268A
Other languages
English (en)
Inventor
Richard Jon Davis
Keith John Page
Original Assignee
Pharmagene Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmagene Lab Ltd filed Critical Pharmagene Lab Ltd
Publication of ZA200210268B publication Critical patent/ZA200210268B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2235—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
ZA200210268A 2000-07-04 2002-12-19 Use of secretin-receptor ligands in treatment of cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). ZA200210268B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0016441.8A GB0016441D0 (en) 2000-07-04 2000-07-04 Therapeutic method

Publications (1)

Publication Number Publication Date
ZA200210268B true ZA200210268B (en) 2003-10-28

Family

ID=9895021

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200210268A ZA200210268B (en) 2000-07-04 2002-12-19 Use of secretin-receptor ligands in treatment of cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD).

Country Status (20)

Country Link
US (4) US6780839B2 (xx)
EP (2) EP1736153B1 (xx)
JP (2) JP2004501977A (xx)
KR (2) KR100881931B1 (xx)
CN (2) CN100584324C (xx)
AT (1) ATE454145T1 (xx)
AU (1) AU2001267729A1 (xx)
CA (1) CA2412839A1 (xx)
CY (1) CY1109937T1 (xx)
DE (1) DE60141054D1 (xx)
DK (1) DK1736153T3 (xx)
ES (1) ES2341562T3 (xx)
GB (3) GB0016441D0 (xx)
HK (1) HK1104959A1 (xx)
MX (1) MXPA02012755A (xx)
NO (2) NO20026119L (xx)
NZ (1) NZ523303A (xx)
PT (1) PT1736153E (xx)
WO (1) WO2002002134A1 (xx)
ZA (1) ZA200210268B (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0507577D0 (en) * 2005-04-14 2005-05-18 Novartis Ag Organic compounds
CN100407816C (zh) * 2005-07-07 2008-07-30 华为技术有限公司 一种群组呼叫的寻呼方法
US8473250B2 (en) 2006-12-06 2013-06-25 Solaredge, Ltd. Monitoring of distributed power harvesting systems using DC power sources
US11569659B2 (en) 2006-12-06 2023-01-31 Solaredge Technologies Ltd. Distributed power harvesting systems using DC power sources
EP2185172A2 (en) * 2007-09-11 2010-05-19 Mondobiotech Laboratories AG Use of follicular gonadotropin releasing peptide as a therapeutic agent in the treatment of streptococcus pneumoniae infection
US20100184676A1 (en) * 2007-09-11 2010-07-22 Dorian Bevec Use of a peptide as a therapeutic agent
US11318190B2 (en) * 2017-05-05 2022-05-03 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating liver disease
RU2721415C1 (ru) * 2019-09-16 2020-05-19 Федеральное государственное бюджетное научное учреждение Дальневосточный научный центр физиологии и патологии дыхания" Способ прогнозирования эффективности коррекции холодовой гиперреактивности дыхательных путей у больных бронхиальной астмой при применении экстрамелкодисперсного аэрозоля для ингаляций беклометазона дипропионата/формотерола фумарата
WO2022065860A1 (ko) * 2020-09-24 2022-03-31 충북대학교 산학협력단 나파모스타트 또는 카모스타트를 포함하는 흡입용 제제
RU2770282C1 (ru) * 2021-07-26 2022-04-15 Федеральное государственное бюджетное научное учреждение «Дальневосточный научный центр физиологии и патологии дыхания» Способ диагностики варианта холодовой гиперреактивности дыхательных путей у больных бронхиальной астмой

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3833722A (en) * 1971-03-16 1974-09-03 D Graybill Method for controlling allergies
GB1472700A (en) * 1974-11-01 1977-05-04 Ono Pharmaceutical Co Guanidinobehzoic acid derivatives and process for preparing the same
DE3402466A1 (de) * 1984-01-25 1985-08-01 Hoechst Ag, 6230 Frankfurt Sekretin und dieses enthaltende mittel zur prophylaxe des aspirations-syndroms
ATE101619T1 (de) * 1990-06-26 1994-03-15 Sanwa Kagaku Kenkyusho Co Vip-analogen und ihre verwendung.
GB9318105D0 (en) 1993-09-01 1993-10-20 Medical Res Council Receptor action
AU709559B2 (en) 1994-04-07 1999-09-02 Proteinix Company Vasoactive intestinal polypeptide
ZA971607B (en) 1996-03-12 1998-08-25 Univ Johns Hopkins Methods of treatment of allergic diseases
JPH09309873A (ja) * 1996-05-22 1997-12-02 Jiyunsei Kagaku Kk メシル酸カモスタットの新規な製造法
WO1998002453A2 (en) 1996-07-15 1998-01-22 Universite Libre De Bruxelles Peptidic ligands having a higher selectivity for the vip1 receptor than for the vip2 receptor
US6197746B1 (en) 1998-05-19 2001-03-06 Repligen Corporation Method of using secretin for treating autism
JP2002501616A (ja) * 1997-05-19 2002-01-15 リプリゲン コーポレーション 自閉的症候群を鑑別診断および治療する際の助けとするための方法
US6020314A (en) * 1998-08-11 2000-02-01 Milkhaus Laboratory, Inc. Methods for treatment of neurological disorders
US6926911B1 (en) * 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
EP1354603A1 (en) * 2000-12-26 2003-10-22 Takeda Chemical Industries, Ltd. Concomitant drugs
GB0507577D0 (en) * 2005-04-14 2005-05-18 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
US20040191238A1 (en) 2004-09-30
KR20030026967A (ko) 2003-04-03
KR20060040754A (ko) 2006-05-10
US20060147384A1 (en) 2006-07-06
CA2412839A1 (en) 2002-01-10
CN100584324C (zh) 2010-01-27
DK1736153T3 (da) 2010-05-10
EP1736153A2 (en) 2006-12-27
GB2368795B (en) 2004-08-04
CN1923187A (zh) 2007-03-07
AU2001267729A1 (en) 2002-01-14
EP1736153B1 (en) 2010-01-06
GB2397522B (en) 2004-09-22
EP1296708A1 (en) 2003-04-02
PT1736153E (pt) 2010-03-24
KR100881931B1 (ko) 2009-02-06
GB2397522A (en) 2004-07-28
NO20026119D0 (no) 2002-12-19
JP2006213728A (ja) 2006-08-17
NO328406B1 (no) 2010-02-15
GB2368795A (en) 2002-05-15
GB0409577D0 (en) 2004-06-02
WO2002002134A1 (en) 2002-01-10
ES2341562T3 (es) 2010-06-22
US20110039759A1 (en) 2011-02-17
NO20061667L (no) 2002-01-07
US6780839B2 (en) 2004-08-24
NO20026119L (no) 2003-02-25
US20020142956A1 (en) 2002-10-03
CY1109937T1 (el) 2014-09-10
JP2004501977A (ja) 2004-01-22
ATE454145T1 (de) 2010-01-15
NZ523303A (en) 2004-11-26
EP1736153A3 (en) 2007-05-23
GB0016441D0 (en) 2000-08-23
HK1104959A1 (en) 2008-02-01
CN1452494A (zh) 2003-10-29
GB0200416D0 (en) 2002-02-27
MXPA02012755A (es) 2004-09-10
DE60141054D1 (de) 2010-02-25

Similar Documents

Publication Publication Date Title
HK1104959A1 (en) Secretin-receptor ligands in the treatment of cystic firbrosis (cf)
MY127812A (en) New use for budesonide and formoterol
USD456197S1 (en) Mattress pad configuration
PT1360202E (pt) Peptídeo do tipo glucagon 2 (glp-2) de longa duração para o tratamento de doenças e distúrbios gastrointestinais
PT1462100E (pt) Composição compreendendo formoterol e um glucocorticosteróide
IL160017A0 (en) Use of a pde4 inhibitor in combination with an anticholinergic agent for the treatment of pulmonary disease such as asthma
EE200000068A (et) Akuutse kopsukahjustuse ja -fibroosi ravi avß6 antagonistidega
IL152770A0 (en) Gabapentin analogues for sleep disorders
NO20052698D0 (no) 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gasatrintestinale lidelser.
AU2001252192A1 (en) Agent for treating illnesses of the tracheobronchial tract, especially chronic obstructive pulmonary disease (copd)
HK1053058A1 (zh) 普拉克索用於治療成癮性疾病的用途
EP1448185A4 (en) TREATMENT OF ASTHMA, CHRONIC OBSTRUCTIVE LUNG DISEASES AND / OR OTHER RESPIRATORY PROBLEMS
IL157145A0 (en) Use of dc23 antagonists for the treatment of neoplastic disorders
GB0004531D0 (en) The treatment of respiratory diseases
WO2002017894A3 (en) Pharmaceutical formulation of salmeterol and fluticasone propionate
HK1038703A1 (zh) 糖皮質類固醇在制備治療輕度/早期copd(慢性阻塞性肺病)的藥物中的應用
GB0507998D0 (en) Novel use of neuronal calcium sensor-1 (NCS-1) in therapy of CNS disorders and in the development of therapeutic agents
AU4335901A (en) Novel therapeutic treatment of chronic obstructive pulmonary disease
HUP0102929A3 (en) Use of levosimendan in the manufacture of a medicament for the treatment of pulmonary hypertension
IL136663A0 (en) Use of substituted amino compounds in the treatment of chronic obstructive pulmonary disease
USD449741S1 (en) Fabric
DE60019104D1 (de) Gentherapy von lungenkrankheiten
IL158809A0 (en) The use of a gatran for the manufacture of a medicament for the treatment of pulmonary fibrosis
DK1411936T3 (da) Anvendelse af thiazolderivater i fremstillingen af et medikament til behandling af kronisk obstruktiv lungesygdom
SI1257254T1 (sl) Farmacevtske oblike, ki vsebujejo antiholinergicno zdravilo za zdravljenje kronicne obstruktivne bolezni pljuc